| 6144- | Cin, | The Cinnamon-Derived Dietary Factor Cinnamic Aldehyde Activates the Nrf2-Dependent Antioxidant Response in Human Epithelial Colon Cells |
| - | in-vitro, | Colon, | HCT116 |
| 6166- | Cin, | Cinnamaldehyde--a potential antidiabetic agent |
| - | in-vivo, | Diabetic, | NA |
| 6140- | Cin, | HCAs, | Cinnamaldehyde: Pharmacokinetics, anticancer properties and therapeutic potential (Review) |
| - | Review, | Var, | NA |
| 1274- | Cin, | Cinnamon bark extract suppresses metastatic dissemination of cancer cells through inhibition of glycolytic metabolism |
| - | vitro+vivo, | BC, | MDA-MB-231 |
| 1567- | Cin, | Cinnamon: Mystic powers of a minute ingredient |
| - | Review, | Var, | NA |
| 1568- | Cin, | Can Cinnamon be the Silver Bullet for Cancer? |
| - | Review, | Var, | NA |
| 952- | Cin, | Cinnamon Extract Reduces VEGF Expression Via Suppressing HIF-1α Gene Expression and Inhibits Tumor Growth in Mice |
| - | in-vitro, | BC, | MDA-MB-231 | - | in-vitro, | GBM, | U251 | - | in-vivo, | Ovarian, | SKOV3 |
| 1055- | Cin, | Cinnamon extract induces tumor cell death through inhibition of NFκB and AP1 |
| - | vitro+vivo, | Melanoma, | NA | - | vitro+vivo, | CRC, | NA | - | vitro+vivo, | lymphoma, | NA |
| 8995- | Citicoline, | Neuroprotection afforded by prior citicoline administration in experimental brain ischemia: effects on glutamate transport |
| - | in-vivo, | Stroke, | NA |
| 8996- | Citicoline, | Effect of citicoline on cognitive function and functional recovery in patients with mild-to-moderate traumatic brain injury: a randomized placebo-controlled trial |
| - | Trial, | Nor, | NA |
| 8997- | Citicoline, | The Real-World Early Neuroprotective Effects of Oral Citicoline Combination in Prodromal Dementia |
| - | Trial, | AD, | NA |
| 8998- | Citicoline, | Rad, | The impact of citicoline on brain mitochondrial dysfunction induced in rats after head irradiation |
| - | in-vivo, | Nor, | NA |
| 8999- | Citicoline, | Citicoline for Supporting Memory in Aging Humans |
| - | Review, | AD, | NA |
| 8993- | Citicoline, | Citicoline protects against lead-induced oxidative injury in neuronal PC12 cells |
| - | in-vitro, | Nor, | PC12 |
| 8992- | Citicoline, | Citicoline: neuroprotective mechanisms in cerebral ischemia |
| - | Review, | Stroke, | NA |
| 8991- | Citicoline, | Chronic citicoline increases phosphodiesters in the brains of healthy older subjects: an in vivo phosphorus magnetic resonance spectroscopy study |
| - | Human, | Nor, | NA |
| 8990- | Citicoline, | Effect of oral CDP-choline on plasma choline and uridine levels in humans |
| - | Trial, | Nor, | NA |
| - | Trial, | AD, | NA |
| 9000- | Citicoline, | The role of citicoline in cognitive impairment: pharmacological characteristics, possible advantages, and doubts for an old drug with new perspectives |
| - | Review, | AD, | NA |
| 2315- | Citrate, | immuno, | Why and how citrate may sensitize malignant tumors to immunotherapy |
| - | Review, | Var, | NA |
| 1593- | Citrate, | Citrate Induces Apoptotic Cell Death: A Promising Way to Treat Gastric Carcinoma? |
| - | in-vitro, | GC, | BGC-823 | - | in-vitro, | GC, | SGC-7901 |
| 1592- | Citrate, | Inhibition of Mcl-1 expression by citrate enhances the effect of Bcl-xL inhibitors on human ovarian carcinoma cells |
| - | in-vitro, | Ovarian, | SKOV3 | - | in-vitro, | Ovarian, | IGROV1 |
| 1591- | Citrate, | The biological significance of cancer: mitochondria as a cause of cancer and the inhibition of glycolysis with citrate as a cancer treatment |
| - | Analysis, | Var, | NA |
| 1583- | Citrate, | Extracellular citrate and metabolic adaptations of cancer cells |
| - | Review, | Var, | NA |
| 1588- | Citrate, | ATP citrate lyase (ACLY) inhibitors: An anti-cancer strategy at the crossroads of glucose and lipid metabolism |
| - | Review, | Var, | NA |
| 1587- | Citrate, | ATP citrate lyase: A central metabolic enzyme in cancer |
| - | Review, | Var, | NA |
| 1586- | Citrate, | Extracellular Citrate Is a Trojan Horse for Cancer Cells |
| - | in-vitro, | Liver, | HepG2 |
| 1585- | Citrate, | Sodium citrate targeting Ca2+/CAMKK2 pathway exhibits anti-tumor activity through inducing apoptosis and ferroptosis in ovarian cancer |
| - | in-vitro, | Ovarian, | SKOV3 | - | in-vitro, | Ovarian, | A2780S | - | in-vitro, | Nor, | HEK293 |
| 1584- | Citrate, | Anticancer effects of high-dose extracellular citrate treatment in pancreatic cancer cells under different glucose concentrations |
| - | in-vitro, | PC, | MIA PaCa-2 | - | in-vitro, | PC, | PANC1 |
| 1582- | Citrate, | Clinical report: A patient with primary peritoneal mesothelioma that has improved after taking citric acid orally |
| - | Case Report, | PerC, | NA |
| 1581- | Citrate, | Hypothesis proved. . .citric acid (citrate) does improve cancer:A case of a patient suffering from medullary thyroid cancer |
| - | Case Report, | Thyroid, | NA |
| 1580- | Citrate, | Citrate activates autophagic death of prostate cancer cells via downregulation CaMKII/AKT/mTOR pathway |
| - | in-vitro, | Pca, | PC3 | - | in-vivo, | PC, | NA | - | in-vitro, | Pca, | LNCaP | - | in-vitro, | Pca, | WPMY-1 |
| 1579- | Citrate, | Effect of Food Additive Citric Acid on The Growth of Human Esophageal Carcinoma Cell Line EC109 |
| - | in-vitro, | ESCC, | Eca109 |
| 1578- | Citrate, | Understanding the Central Role of Citrate in the Metabolism of Cancer Cells and Tumors: An Update |
| - | Review, | Var, | NA |
| 1577- | Citrate, | Citric acid promotes SPARC release in pancreatic cancer cells and inhibits the progression of pancreatic tumors in mice on a high-fat diet |
| - | in-vivo, | PC, | NA | - | in-vitro, | PC, | PANC1 | - | in-vitro, | PC, | PATU-8988 | - | in-vitro, | PC, | MIA PaCa-2 |
| 1576- | Citrate, | Targeting citrate as a novel therapeutic strategy in cancer treatment |
| - | Review, | Var, | NA |
| 1574- | Citrate, | Citrate Suppresses Tumor Growth in Multiple Models through Inhibition of Glycolysis, the Tricarboxylic Acid Cycle and the IGF-1R Pathway |
| - | in-vitro, | Lung, | A549 | - | in-vitro, | Melanoma, | WM983B | - | in-vivo, | NA, | NA |
| 6146- | Citrate, | Citric acid promotes SPARC release in pancreatic cancer cells and inhibits the progression of pancreatic tumors in mice on a high‐fat diet |
| - | in-vitro, | PC, | NA |
| 6147- | Citrate, | The dual role of citrate in cancer |
| - | Review, | Var, | NA |
| 6148- | Citrate, | immuno, | Sodium Citrate Nanoparticles Induce Dual-Path Pyroptosis for Enhanced Antitumor Immunotherapy through Synergistic Ion Overload and Metabolic Disturbance |
| - | in-vitro, | Var, | NA |
| 6155- | CoQ10, | BPGbio Highlights Groundbreaking Data on BPM31510 for Mitochondrial Diseases at the Inaugural Mitochondrial Transplantation and Next Generation Therapeutics Conference |
| - | Review, | Var, | NA |
| - | in-vitro, | Colon, | Caco-2 |
| 6158- | CoQ10, | Coenzyme Q10 Ameliorates Pancreatic Fibrosis via the ROS-Triggered mTOR Signaling Pathway |
| - | in-vitro, | PC, | NA |
| 6157- | CoQ10, | BPM31510: Targeting the tumor microenvironment (TME) via mitochondrial-mediated ROS production |
| - | Review, | GBM, | NA |
| 6156- | CoQ10, | Metabolic Regulation of Ferroptosis in Breast Cancer |
| - | Review, | Var, | NA |
| 6154- | CoQ10, | Coenzyme Q10 (BPM31510-IV in clinical trials) increases mitochondrial Q-pool and modulates electron transport chain function to elicit cell death in pancreatic cancer cells |
| - | vitro+vivo, | PC, | MIA PaCa-2 |
| - | vitro+vivo, | GBM, | U251 |
| 6152- | CoQ10, | doxoR, | Phase I Randomized, Placebo-Controlled, Cross-Over Dose-Finding Study of Coenzyme Q10 on Doxorubicin Pharmacokinetics during Breast Cancer Treatment |
| - | Trial, | BC, | NA |
| 4258- | CoQ10, | Neuroprotective effects of coenzyme Q10-loaded exosomes obtained from adipose-derived stem cells in a rat model of Alzheimer's disease |
| - | in-vivo, | AD, | NA |
| 4257- | CoQ10, | Dietary intake of coenzyme Q10 reduces oxidative stress in patients with acute ischemic stroke: a double-blind, randomized placebo-controlled study |
| - | Trial, | Stroke, | NA |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:% Target#:% State#:% Dir#:%
wNotes=0 sortOrder:rid,rpid